The drug can now be used in combination with ursodeoxycholic acid (UDCA) in patients with an inadequate response to UDCA, or as a monotherapy in those who are unable to tolerate UDCA.
The recommendation makes Iqirvo the first medicine for PBC to be approved for use on the NHS in nearly a decade and comes just two weeks after the Medicines and Healthcare products Regulatory Agency granted marketing authorisation to the drug in this setting…
